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Background: The effects of body mass index (BMI) and reproductive factors may vary among breast
cancer molecular subtypes, evidence of which is lacking in East Asia.
Methods: From 2002 to 2010, 1256 breast cancer patients and 1416 healthy women were recruited.
Anthropometric and reproductive factors were collected from medical charts. Breast cancer subtype was
defined by ER, PR, and HER2 status. Polytomous logistic regression was used to evaluate associations
between risk factors and breast cancer subtypes, with subgroup analysis by menopausal status. A meta-
analysis of relevant published studies in East Asia was also performed.
Results: In our case-control study, late menarche was negatively associated with luminal tumor risk
(Ptrend ¼ 0.03). Higher BMI was associated with risk of both luminal and triple-negative tumors
(Ptrend<0.001). Late age at first live birth was associated with a 1.41- to 2.08-fold increased risk of all
subtypes, while late menopause increased risk by 2.62e5.56 times. Heterogeneity of these associations
was not detected for different menopausal statuses. The meta-analysis revealed a positive dose-response
relationship between BMI and risk of both luminal and ER-PR- subtypes (Ptrend<0.05). Early menarche
and nulliparity increased luminal tumor risk by 1.39 and 1.26 times, respectively. Non-breastfeeding also
increased the risk of all subtypes.
Conclusions: For East Asian women, overweight, late menopause, and lack of breastfeeding appear to
increase risk of both luminal and ERPR tumors. Early menarche and nulliparity mainly impacted
luminal tumor risk. These associations were not impacted by menopausal status.
© 2016 The Authors. Publishing services by Elsevier B.V. on behalf of The Japan Epidemiological
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Breast cancer is the most common cancer among women
worldwide, with an age-adjusted incidence of 43.3 cases per
100,000 people. Although the incidence of breast cancer is lower in
East Asia compared with the West, there has been a rising trend in
recent years, with an incidence in 2012 of 27.0 cases per 100,000
people.1
The heterogeneity of breast cancer has been widely recognized
in the past decades. Subtypes include luminal, HER2-enriched, andngdu, Sichuan 610041, China.
demiological Association.
Elsevier B.V. on behalf of The Japa
d/4.0/).basal-like types, based on global gene expression analyses.2 Breast
cancer subtypes carry distinct clinicopathologic characteristics and
prognoses, which suggests heterogeneous etiologies.3e9 Previous
studies showed that women's body size10 and reproductive factors,
including early menarche, late menopause, nulliparity, late age at
first live birth, and no lactation, had a relatively pronounced effect
on elevating luminal tumor risk,11 while several recent studies have
found a significant association between these factors and triple-
negative tumors.10,11 However, the results of epidemiological
studies have not been consistent.
Breast cancer risk factors are known to be distributed differently
depending on menopausal status and race.12 Distribution differ-
ences in molecular subtypes among women of different meno-
pausal status and ethnicity have also been demonstratedn Epidemiological Association. This is an open access article under the CC BY-NC-ND
H. Li et al. / Journal of Epidemiology 27 (2017) 143e151144previously.13 Compared with white women, for example, East Asian
women have a higher risk of triple-negative and HER2-enriched
tumors.14 Luminal tumors are more commonly diagnosed among
postmenopausal Caucasian women in Western countries,4 but
conversely are more prevalent among premenopausal women in
East Asia.15
The difference in subtype distribution between white and black
women has been intensively studied in Western countries, while
little data are available for East Asian women, especially in China,
where the incidence of breast cancer rose from 20.13 to 42.55 cases
per 100,000 people from 2005 to 2009.16,17 The few Chinese studies
that have been published reported inconsistent results for associ-
ations between common risk factors and different tumor subtypes,
and these studies did not evaluate possible associations in groups of
women with differing menopausal statuses.15,18,19 Furthermore,
relevant studies from China were all conducted in the eastern part
of the country, while China's western regions have disparate dis-
tributions of body size and reproductive factors due to varying
levels of economic development.13
Thus, we conducted this population-based case-control study in
southwestern China to evaluate associations among BMI, repro-
ductive factors, and breast tumor subtypes. Subgroup analysis was
performed by menopausal status. We also conducted a meta-
analysis to assess these associations among East Asian women.
Our results supply some of the first data on these associations from
less developed areas of China, and our meta-analysis is the first to
pool the results of relevant studies in East Asia.
Methods
Study subjects
From 2002 to 2010 at Sichuan Cancer Hospital, 1256 patholog-
ically and newly confirmed invasive breast cancer cases with mo-
lecular subtypes diagnosed in breast surgery were enrolled in the
study. To form the control group, 1416 healthy women undergoing
routine physical examinations during the same time period were
randomly selected and frequency-matched to the cases by age. The
controls were recruited at the Chengdu Children's and Women's
Hospital, the leading institution providing medical treatment and
health care for women and children in Sichuan Province, which
supplies routine health examinations to women in the area. Con-
trols with any known malignancy or mental disorder were
excluded. The study protocol was approved by the institutional
review boards of Sichuan University, Chengdu Children's and
Women's Hospital, and Sichuan Cancer Hospital.
Data collection
Information on breast cancer risk factors was collected from the
participants' medical records. Specifically, height and weight were
measured, and information on other risk factors, including age at
diagnosis, menopausal status, age at menarche, age at menopause,
age at first live birth, parity, and breastfeeding were collected
during interviews by trained nurses when the participants were
admitted to the hospital for the first time or during the physical
examination. Women who had lactated for at least 1month were
classed as “ever breastfed.” A woman was defined as post-
menopausal if she had undergone natural menopause (if she had
experienced 12 continuous months without a menstrual cycle
before any endocrine treatment or oophorectomy), bilateral oo-
phorectomy, or irradiation of the ovaries before 50 years of age. If a
woman was aged 50 or older and no longer experienced
menstruation, she was also considered postmenopausal. BMI was
calculated as body weight (kg)/height2 (m2) and used as a measureof general obesity. The response rates for both cases and controls
were 100%.
Biomarker detection
The ER, PR, and HER2 status of the patients was extracted from
medical records. Tumor type was determined using immunohis-
tochemical (IHC) assay at the pathology department of Sichuan
Cancer Hospital. Positive ER and PR status was defined as 1% of
tumor cells presenting positive nuclear staining. The results of
HER2 were scored semi-quantitatively according to the estimated
percentage of positively stained tumor cell nuclei and the intensity
of nuclear staining (for no staining, þ1 for weak intensity, þ2 for
intermediate intensity, and þ3 for strong intensity). Results of “”
or “þ1” were classed as HER2 negative and “þ3” as positive.20 A
fluorescence in situ hybridization (FISH) test was recommended to
“þ2” patients to determine the HER2 expression status in the breast
tumor. In our study, 20% of “þ2” patients opted for the FISH test.
Considering that less than 20% of women with “þ2” were diag-
nosed as HER2 positive by FISH, we treated those who did not opt
for FISH as HER2 negative.21
All the patients were grouped into one of the following three
categories: luminal (ERþ or PRþ, HER2þ or HER2-), HER2-enriched
(ER, PR, HER2þ), or triple-negative (ER, PR, HER2).
Data analysis
BMI was categorized using the World Health Organization
(WHO) definition of <18.5 kg/m2 as underweight, 18.5e24.9 kg/m2
as normal, 25e29.9 kg/m2 as overweight, and 30 kg/m2 as obese.
We combined the overweight and obese groups due to the low
proportion of obesity in the subjects (2%). Age at menarche and age
at first live birth were divided into two categories according to
common cutoff values reported previously.22 Due to the small
number of nulliparous women (<5%), we did not include parity in
the regression analysis. In the subgroup analysis performed ac-
cording to menopausal status, all continuous variables were cate-
gorized into two levels due to the limited sample size in tumor
subgroups. One-way analysis of variance and chi-square tests were
used to compare the distribution of selected factors between con-
trols and subgroups of cases. The distribution differences between
groups were measured using trend chi-square tests. Polytomous
logistic regression, which is suitable for multiple outcomes data,
was used to evaluate the associations between BMI, reproductive
factors, and risks for molecular subtypes. Theweighted least square
(WLS) method was used to test the heterogeneity of associations
between risk factors and breast cancer subtypes. Data were
analyzed with SPSS 17.0 software (IBM Corp, Armonk, NY, USA). All
p-values were subjected to a two-tailed test, with an alpha level of
0.05 for significance testing.
Meta-analysis
Literature search
We searched for studies on the relationship between common
factors and risk of breast cancer molecular subtypes among East
Asian women in PubMed, Ovid, the Chinese Biomedical Literature
Analysis and Retrieval System, and the Chinese National Knowledge
Infrastructure for the period up to August 2015 using the following
keyword combinations: (‘‘risk factors’’ OR “reproductive factors”
OR “body mass index”) AND (‘‘breast cancer’’ OR “breast tumor” OR
“breast malignancy”) AND (“subtypes” OR “hormonal status”) AND
(‘‘East Asia’’ OR ‘‘China’’ OR “Japan” OR “Korea” OR “Mongolia”). In
addition, we checked the references of relevant papers for citations
of similar studies. We included in our analysis studies with
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HER2 status. Only studies with sufficient data to estimate an odds
ratio (OR) with 95% confidence interval (CI) were included. If
multiple publications reported the same or overlapping data, the
publication with the largest sample size or most recent publication
was selected for inclusion.
Quality assessment
The Newcastle-Ottawa Quality Assessment Scale was used to
assess the validity of the selected studies. Two of the itemswere not
applicable for evaluating the included studies: (a) ‘‘structured
interview where blind to case/control status’’; and (b) “same
method of ascertainment for cases and controls” (the invasive
histopathological diagnostic procedure is unsuitable for healthy
control subjects). Thus, a total of six criteria with seven scores were
used in the quality assessment. A study that met six or seven
criteria was ranked as “A”, a study that met four or five criteria was
ranked “B”, and a study was ranked “C” if it met fewer than four
criteria.
Data extraction
For each eligible study, the following informationwas extracted:
the first author's name, year of publication, country of origin, study
design, menopausal status of cases, year subjects were recruited,
sample size, tumor subtypes, matched factors, and adjusted con-
founding factors. The literature search, quality assessment, and
data extractionwere independently performed by two researchers.
If divergence existed, they discussed with the third investigator and
came to a final decision.
Statistical analysis
Pooled ORs and 95% CIs for the associations between BMI,
reproductive factors, and breast cancer molecular subtypes were
calculated via dividing the observed frequencies of categories by
the unified cutoff values of eligible studies. Heterogeneity among
the included articles was estimated by a chi-square-based Q-test. If
significant heterogeneity was not detected (P > 0.05), the Mantel-
Haenszel method was used to estimate the pooled OR and 95% CI.
Otherwise, the DerSimonian and Laird method was selected. TheTable 1
Characteristics of breast cancer cases and controls.a
Risk factors Controls n ¼ 1416 Luminal n ¼ 898
Age, years 47.96 (10.07) 47.73 (10.93)
BMI, kg/m2 22.32 (2.66) 23.01 (2.88)
Age at menarche 14.28 (1.68) 14.27 (1.82)
Age at first live birth 25.04 (2.68) 24.50 (2.78)
Age at menopause 48.98 (2.97) 48.97 (4.29)
Menopause status
No 831 (58.8) 554 (61.7)
Yes 585 (41.2) 344 (38.3)
Parity
0 39 (2.8) 28 (3.1)
1 1377 (97.2) 870 (96.9)
Breastfeedingc
No 95 (6.9) 49 (5.6)
Yes 1282 (93.1) 821 (94.4)
Family history of breast cancer
No 1391 (98.2) 860 (95.8)
Yes 25 (1.8) 38 (4.2)
BMI, body mass index.
a Mean (standard deviation): age, BMI, age at menarche, age at fist live birth, age at
history of breast cancer.
b One-way analysis of variance: age, BMI, age at menarche, age at first live birth, age a
feeding, family history of breast cancer.
c Among parous women.WLSmethodwas used to quantify the heterogeneity of associations
between risk factors and breast cancer subtypes. Egger's regression
test was used to determine publication bias.23 Publication bias is
considered to be present if the p-value of the intercept (a) is less
than 0.05. Sensitivity analysis was performed via excluding the
study with the largest weight and then evaluating the impact of the
change on the pooled OR. Crude ORs with 95% CIs for each study, Q-
tests, and pooled ORs with 95% CI were calculated using Review
Manager 5.0 (Nordic Cochrane Center, Copenhagen, Denmark). The
Egger's andWLS tests were performed with SPSS 17.0. The p-values
were subjected to a two-tailed test, with an alpha level of 0.05 for
significance testing.Results
The case-control study
Of the 1256 cases, 898 tumors (71.4%) were classified as luminal,
55(4.3%) as HER2-enriched, and 303(24.1%) as triple-negative
(Table 1). There was no statistical difference in average age, post-
menopausal age, parity, or breastfeeding status among controls and
the subtype groups (P > 0.05) (Table 1). The distribution of BMI, age
at menarche, age at first live birth, and menopausal status varied
among groups (P  0.05) (Table 1).
Among all subjects, early age at menarche (13 years old)
increased the risk of luminal tumor compared with women who
had undergone menarche at 15 years of age or older (ORluminal1.28;
95%CI, 0.99e1.67; Ptrend<0.05). The risk of luminal tumor rose along
with increasing BMI (18.5e24.9 vs. <18.5: ORluminal1.58; 95%CI,
1.02e2.43; 25 vs. <18.5: ORluminal2.58; 95%CI, 1.60e4.14;
Ptrend<0.001). A BMI of 25 kg/m2 or more also increased triple-
negative tumor risk (ORtriple-negative2.96; 95%CI, 1.34e6.54;
Ptrend<0.001). Compared with women who had their first live birth
when younger than 25 years old, those with later age at first live
birth (25e29 years old) had an elevated risk of all subtypes (ORlu-
minal1.41; 95%CI, 1.17e1.70; ORHER2-enriched2.08; 95%CI, 1.15e3.77;
ORtriple-negative1.34; 95%CI, 1.02e1.76). The difference in associations
betweenmenarche age and the three subtypes of breast cancer was
statistically significant (Pheterogeneity<0.05) (Table 2).HER2-enriched n ¼ 55 Triple-negative n ¼ 303 P-valueb
48.62 (8.97) 49.54 (10.74) 0.06
22.65 (2.26) 23.20 (3.03) <0.001
14.87 (1.78) 14.49 (1.84) 0.02
24.51 (2.50) 24.18 (2.69) <0.001
49.24 (4.12) 48.52 (4.35) 0.44
30 (54.5) 154 (50.8) 0.01
25 (45.5) 149 (49.2)
0 (0.0) 15 (5.0) 0.11
55 (100.0) 288 (95.0)
5 (9.1) 21 (7.3) 0.51
50 (90.9) 267 (92.7)
54 (98.2) 290 (95.7) 0.002
1 (1.8) 13 (4.3)
menopause. n (%): menopause status, parity, breast feeding, tumor subtype, family
t menopause; Chi-square test: menopause status; Fisher's exact test: parity, breast
Table 2
Associations between risk factors and breast cancer subtypes in overall cases and controls.a
Risk factors Control, n (%) n ¼ 1416 Luminal n ¼ 898 HER2-enriched n ¼ 55 Triple-negative n ¼ 303 Phd
n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI)
Age, years
<40 313 (22.1) 221 (24.6) 1.00 8 (14.5) 1.00 48 (15.8) 1.00
40e59 896 (63.3) 542 (60.4) 0.72 (0.50e1.06) 41 (74.5) 0.53 (0.15e1.91) 206 (68.0) 0.67 (0.38e1.19) 0.01
60 207 (14.6) 135 (15.0) 0.85 (0.67e1.07) 6 (11.0) 1.41 (0.62e3.24) 49 (16.2) 1.27 (0.86e1.87) 0.15
Ptrend ¼ 0.42b Ptrend ¼ 0.64b Ptrend ¼ 0.04b
Menopausal status
Yes 585 (41.3) 343 (38.2) 1.00 25 (45.5) 1.00 149 (49.2) 1.00
No 831 (58.7) 555 (61.8) 1.32 (1.05e1.65) 30 (54.5) 1.03 (0.54e1.96) 154 (50.8) 0.96 (0.71e1.33) 0.02
BMI, kg/m2
<18.5 82 (5.8) 35 (3.9) 1.00 2 (3.6) 1.00 8 (2.6) 1.00
18.5e24.9 1149 (81.1) 683 (76.1) 1.58 (1.02e2.43) 46 (83.6) 1.41 (0.33e5.96) 223 (73.6) 1.77 (0.84e3.74) 0.70
25 185 (13.1) 180 (20.0) 2.58 (1.60e4.14) 7 (12.8) 1.27 (0.25e6.36) 72 (23.8) 2.96 (1.34e6.54) 0.39
Ptrend < 0.001b Ptrend ¼ 0.76b Ptrend < 0.001b
Age at menarche, years
15 925 (65.3) 550 (61.2) 1.00 44 (80.0) 1.00 206 (68.0) 1.00
14 313 (22.1) 213 (23.7) 1.16 (0.94e1.43) 6 (10.9) 0.45 (0.19e1.08) 59 (19.5) 1.01 (0.73e1.41) 0.03
13 178 (12.6) 135 (15.1) 1.28 (0.99e1.67) 5 (9.1) 0.75 (0.29e1.95) 38 (12.5) 1.22 (0.81e1.83) 0.18
Ptrend ¼ 0.034b Ptrend ¼ 0.06b Ptrend ¼ 0.55b
Age at first live birth, yearsc
24 634 (46.0) 370 (42.5) 1.00 20 (36.4) 1.00 134 (46.5) 1.00
25e29 682 (49.5) 469 (53.9) 1.41 (1.17e1.70) 34 (61.8) 2.08 (1.15e3.77) 147 (51.0) 1.34 (1.02e1.76) 0.34
30 61 (4.6) 31 (3.6) 1.19 (0.75e1.90) 1 (1.8) 0.86 (0.11e6.72) 7 (2.4) 0.93 (0.41e2.13) 0.56
Ptrend ¼ 0.28b Ptrend ¼ 0.37b Ptrend ¼ 0.50b
Breastfeedingc
Yes 1282 (93.1) 821 (94.4) 1.00 50 (90.9) 1.00 267 (92.7) 1.00
No 95 (6.9) 49 (5.6) 0.92 (0.64e1.32) 5 (9.1) 1.57 (0.60e4.10) 21 (7.3) 1.24 (0.75e2.05) 0.47
BMI, body mass index; CI, confidence interval; OR, odds ratio.
a Odds ratios adjusted for the other factors in this table and family history of breast cancer.
b P-value for trends calculated by trend chi-square.
c Among parous women.
d P-value of the heterogeneity of exposure-disease ORs between luminal, HER2-enriched, and triple-negative subtypes.
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ciated with elevated risk of luminal and triple-negative subtypes
(ORluminal1.88; 95%CI, 1.31e2.69; ORtriple-negative2.51; 95%CI,
1.53e4.12), and late age at first live birth (25 years old) was linked
with increased risk of luminal tumor (ORluminal1.39; 95%CI,
1.10e1.76) (Table 3). In postmenopausal women, overweight and
obesity (BMI  25 kg/m2) was associated with an increased risk of
the luminal subtype only (ORluminal1.48; 95%CI, 1.08e2.04).
Increased age at first live birth (25 years) was associated with
elevated risk of luminal tumor (ORluminal1.41; 95%CI, 1.04e1.90),
and womenwith older menopausal age (55 years old) had higher
risk of all subtypes (ORluminal3.11; 95%CI, 1.61e6.02; ORHER2-
enriched5.56; 95%CI, 1.41e21.93; ORtriple-negative2.65; 95%CI,
1.12e6.33). In postmenopausal women, the associations between
age at menarche and tumor subtypes still showed significant het-
erogeneity (P ¼ 0.05) (Table 3).
Meta-analysis
Among the 259 retrieved studies, 176 studies were irrelevant, 12
were case series studies, 49 focused on genetic and other envi-
ronmental factors, and the outcome of 10 studies was survival
status. Of the remaining 12 studies, the risk factors in Yoo's,24
Suzuki's,25 and Tamaki's26 studies from Japan, Chung's study from
Korea,27 and Adam's study from China28 lacked frequencies, and
one study including subjects from Vietnam and China reported the
molecular subtypes according to single ER status, PR status, or
HER2 status.29 Among the remaining six studies,18,19,30e33 two
studies from Japan were performed on an overlapping population.
In considering whether it was feasible to pool the data, we used the
frequencies of BMI from Sueta et al33 and that of reproductive
factors reported by Islam30 to calculate pooled effects separately.
The flow diagram of the study selection is shown in Fig. 1.Among the six included studies, two were ranked as “A” and
four were ranked as “B” quality. Two studies were from China and
four were from Japan (Table 4). Few studies were eligible to be
included in the pooled analysis according to menopausal status, so
we only conducted the meta-analysis in controls. Thus, a total of
8,637cases and 13,001 controls (including those from our own
case-control study) were included in the final analysis. The cate-
gories of menopausal age and age at menarche in our own case-
control study were re-divided to be consistent with the majority
of the selected studies. The breast tumor molecular subtypes were
classified as luminal (ERþ/PRþ) and ERPR. When possible, the
latter was further divided into two groups: HER2-enriched and
triple-negative.
Compared with women with a BMI of less than 18.5 kg/m2,
those with a BMI between 18.5 kg/m2 and 24.9 kg/m2 had
marginally increased risk of both luminal (ORluminal1.20; 95%CI,
0.96e1.49) and ERPR tumors (ORERPR1.43; 95%CI, 1.00e2.05).
A BMI of more than 25 kg/m2 conferred higher risks of both sub-
types (ORluminal1.75; 95%CI, 1.30e2.35 and ORERPR1.95; 95%CI,
1.04e3.65). Women who experienced menopause after 50 years of
age also had elevated risk of luminal and ERPR tumors (ORlu-
minal1.15; 95%CI, 1.00e1.32 and ORERPR1.19; 95%CI, 1.00e1.43).
Younger age at menarche (12 years old) (ORluminal1.39; 95%CI,
1.23e1.57) and nulliparity (ORluminal1.26; 95%CI, 1.11e1.44) only
increased the risk of luminal tumor. Lack of breastfeeding history
increased the risk of all the molecular subtypes (ORluminal1.35; 95%
CI, 1.05e1.74; ORHER2-enriched1.97; 95%CI, 1.39e2.80; and ORtriple-
negative1.85; 95%CI, 1.06e3.21). The differences in associations be-
tween age at menarche, parity, age at first live birth, breastfeeding,
and breast tumor subtypes were significant (all Pheterogeneity<0.05)
(Table 5). After removing the study with the largest weight, the
significant associations between menopausal age and luminal tu-
mor risk and between breastfeeding and triple-negative tumor
Table 3
Associations between risk factors and breast cancer subtypes by menopausal status.a
Risk
factorsb
Premenopausal Phd Postmenopausal Phd
Control Luminal HER2-enriched Triple-negative Control Luminal HER2-enriched Triple-negative
n ¼ 831 n ¼ 555 n ¼ 30 n ¼ 154 n ¼ 585 n ¼ 343 n ¼ 25 n ¼ 149
n (%) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI) n (%) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI)
Age, years
<40 313
(37.7)
221
(39.8)
1.00 8
(26.7)
1.00 48
(31.2)
1.00 e
40e59 518
(62.3)
334
(60.2)
0.85
(0.67e1.07)
22
(73.3)
1.43
(0.62e3.29)
106
(68.8)
1.25
(0.84e1.84)
0.11 378
(64.6)
208
(60.6)
1.00 19
(76.0)
1.00 100
(67.1)
1.00
60 e 207
(35.4)
135
(39.4)
0.80
(0.58e1.09)
6
(24.0)
0.31
(0.11e0.83)
49
(32.9)
0.52
(0.33e0.81)
0.22
BMI, kg/m2
<25 765
(92.1)
478
(86.1)
1.00 25
(83.3)
1.00 126
(81.8)
1.00 467
(79.8)
240
(70.0)
1.00 23
(92.0)
1.00 106
(71.1)
1.00
25 66
(7.9)
77
(13.9)
1.88
(1.31e2.69)
5
(16.7)
2.25
(0.82e6.17)
28
(18.2)
2.51
(1.53e4.12)
0.55 118
(20.2)
103
(30.0)
1.48
(1.08e2.04)
2
(8.0)
0.31
(0.07e1.35)
43
(28.9)
1.24
(0.80e1.92)
0.11
Menarche age, years
14 507
(61.0)
318
(57.3)
1.00 20
(66.7)
1.00 99
(64.3)
1.00 418
(71.5)
232
(67.6)
1.00 24
(96.0)
1.00 107
(71.8)
1.00
<14 324
(39.0)
237
(42.7)
1.17
(0.93e1.47)
10
(33.3)
0.83
(0.38e1.83)
55
(35.7)
0.98
(0.67e1.43)
0.29 167
(28.5)
111
(32.4)
1.25
(0.92e1.69)
1
(4.0)
0.14
(0.02e1.03)
42
(28.2)
1.20
(0.79e1.83)
0.05
Age at first live birth, yearsc
<25 391
(49.1)
238
(44.4)
1.00 12
(40.0)
1.00 70
(47.3)
1.00 243
(41.9)
132
(39.5)
1.00 8
(32.0)
1.00 64
(45.7)
1.00
25 406
(50.9)
298
(55.6)
1.39
(1.10e1.76)
18
(60.0)
1.72
(0.79e3.74)
78
(52.7)
1.43
(0.98e2.09)
0.74 337
(58.1)
202
(60.5)
1.41
(1.04e1.90)
17
(68.0)
2.45
(0.97e6.18)
76
(54.3)
1.21
(0.81e1.81)
0.40
Breastfeedingc
Yes 748
(93.9)
507
(94.6)
1.00 27
(90.0)
1.00 140
(94.6)
1.00 534
(92.1)
314
(94.0)
1.00 23
(92.0)
1.00 127
(90.7)
1.00
No 49
(6.1)
29
(5.4)
0.98
(0.60e1.59)
3
(10.0)
1.87
(0.54e6.47)
8
(5.4)
1.00
(0.46e2.20)
0.60 46
(7.9)
20
(6.0)
0.83
(0.48e1.46)
2
(8.0)
1.40
(0.31e6.40)
13
(9.3)
1.44
(0.74e2.80)
0.54
Age at post-menopause, years
<55 e 570
(97.4)
316
(92.1)
1.00 22
(88.0)
1.00 140
(94.0)
1.00
55 e 15
(2.6)
27
(7.9)
3.11
(1.61e6.02)
3
(12.0)
5.56
(1.41e21.93)
9
(6.0)
2.65
(1.12e6.33)
0.63
BMI, body mass index; CI, confidence interval; OR, odds ratio.
a Odds ratios adjusted for the other factors in this table and family history of breast cancer.
b Considering the limited sample sizes in tumor subgroups, all the continuous variables were categorized into two levels, including BMI, age at menarche, and age at first live
birth.
c Among parous women.
d P-value of heterogeneity of exposure-disease odds ratios among luminal, HER2-enriched, and triple-negative subtypes.
H. Li et al. / Journal of Epidemiology 27 (2017) 143e151 147disappeared. The other pooled ORs and 95% CIs were stable
(eTable 1). Publication bias was not detected for the overall analysis
(all P > 0.05) (eTable 2).Discussion
In this population-based case-control study in southwestern
China, we found that overweight and obesity and late menopause
increased the risk of both luminal and triple-negative tumors.
These findings were consistent with those of our meta-analysis of
risk factors for East Asian women. Overweight and obesity may
affect breast cancer by various mechanisms, including increasing
estrogen synthesis, causing insulin resistance, inhibiting the syn-
thesis of sex hormone-binding globulin (SHBG), and promoting
systemic inflammation.34
In our case-control study, we observed that, in postmenopausal
women, higher BMI only elevated risk of the luminal tumor sub-
type. Previous studies observed similar results, including the Cali-
fornia Teacher Study35 and the Breast Cancer Surveillance
Consortium (BCSC) cohort study36 from the United States, the Eu-
ropean Prospective Investigation into Cancer and Nutrition (EPIC)
study, and case-control studies from Japan and China32,33,37 (RRs
and ORs ranged from 1.17 to 2.14, with 95%CIs excluding 1). In
general, the magnitude of the associations observed in thesestudies was similar to that observed in the present study. We also
found that overweight and obesity were associated with increased
premenopausal risk of both luminal and triple-negative tumors. For
triple-negative tumors, a meta-analysis of case-case studies found
that obesity was associated with an increased triple-negative tu-
mor risk among premenopausal women (OR1.43; 95% CI,
1.23e1.65),38 which was similar to our results. For luminal sub-
types, Yang's meta-analysis,39 which included 12 population-based
American studies, found a 1.36-times higher risk of premenopausal
luminal tumors for those with higher BMI. However, the EPIC
study37 and the case-control study from Japan32 reported a small
inverse association between BMI and premenopausal luminal tu-
mors (HRs and ORs ranged from 0.79 to 0.93, with 95%CIs excluding
1), while the Shanghai study18 found no significant association.
Differing prevalence of obesity and subtypes in different pop-
ulations may contribute to the disparity of these results.
An experimental study found that obesity was positively
correlated with levels of leptin, the addition of which increased cell
proliferation in ERa-positive breast cancer cell lines.40 And an
experiment using the C3(1)-TAg murine model demonstrated that
weight loss could prevent basal-like breast cancer by blocking the
obesity-responsive pro-tumorigenic hepatocyte growth factor/c-
Met pathway.41 Thus, theoretically, obesity may increase both
luminal and triple-negative tumor risk in premenopausal and
Fig. 1. The flow diagram of the study selection.
Table 4
Characteristics of included studies in meta-analysis.
First author
(published year)
Region Menopausal
status
Study
design
Year subjects
were recruited
Sample size,
case/control
Type of tumor Risk
factorsa
Matched
factor
Adjusted
factorsb
Rank
(Number
of qualified
items)c
Bao et al. 2011.18 China total/pre/post PCC 1996e1998/
2002e2005
2676/3474 ERþ/PRþ, ER/PR,
ERþ/PR, ER/PRþ
B,C,D,E,F age 1, 2, 3, 4, 5,
6, 7, 8, 9, 10.
A (6)
Islam et al. 2012.25 Japan total HCC 2003e2005 706/1412 Luminal, HER2-enriched,
TN
B,C,D,E,F age,
menopausal
status
1, 4, 5, 6, 13,
17, 18
B (5)
Sueta et al. 2012.28 Japan total/pre/post HCC 2001e2005 715/1430 Luminal, HER2-enriched,
TN
A age,
menopausal
status
1, 4, 5, 9, 12,
13, 14,15,16.
B (5)
Kawai et al. 2012.26 Japan total HCC 1997e2009 1092/3160 ERþ/PRþ,ER/PR,
ERþ/PR,ER/PRþ
A,B,C,D,E e 1, 5, 6,17,18,
19,20, 21.
A (6)
Miyagawa et al. 2013.27 Japan total/pre/post PCC 2005e2012 615/682 Luminal A, Luminal B,
HER2-enriched, TN
C e 1,4,9,12,22 B (5)
Xing et al. 2009.19 China total PCC 2001e2009 1417/1587 Luminal A, Luminal B,
HER2-enriched, TN
B,C,D,E age 1,4,9,12,13,
23,24,25
B (4)
Present study China total/pre/post PCC 2002e2012 1416/1256 Luminal, HER2-enriched,
TN
A,B,C,D,E,F age 1,6,9,12,13,
14,22, 26
e
ER, estrogen receptor; HCC, hospital-based case-control study; PCC, population-based case-control study; PR. progesterone receptor; TN, triple-negative.
a Risk factors included in this meta-analysis: A. BMI B. age at menarche C. parity D. age at first live birth E. breastfeeding F. menopausal age.
b Risk factors adjusted for in the studies: 1. age, 2. education, 3. history of breast fibroadenoma, 4. family history of breast cancer, 5. physical exercise, 6. BMI, 7. waist-to-hip
ratio, 8. history of live birth, 9. parity, 10. study phase, 11. years of menstruation, 12. age at menarche, 13. menopausal status, 14. age at first live birth, 15. hormone use, 16.
referral pattern, 17. smoking, 18. alcohol use, 19. occupation, 20. year of recruitment, 21. area of residence, 22. age at menopause, 23. induced abortion, 24. spontaneous
abortion, 25. history of hysteromyoma, and 26. breastfeeding.
c Results of quality assessment and number of qualified items according to the Newcastle-Ottawa Quality Assessment Scale (NOS) for case-control studies.
H. Li et al. / Journal of Epidemiology 27 (2017) 143e151148postmenopausal women. Accordingly, the heterogeneous results
for the effects of BMI on breast tumor subtypes were not significant
in our case-control study and meta-analysis. The mechanism of
obesity's impact on tumor risk in women of different menopausal
statuses merits further study. Based on our results, it could be
deduced that, although the rate of obesity is relatively low for
Chinese women (5.6%),42 premenopausal women may be relatively
sensitive to obesity as a risk factor for breast cancer. Our resultshighlight the importance of weight control in premenopausal
women.
Early age at menarche and delayed menopause may prolong the
exposure period of estrogen and enhance breast cancer risk. Our
case-control study found that, of these two factors, only early
menarche was associated with luminal tumor risk, a relationship
also found in our subsequent meta-analysis in East Asians. This
finding also accords with Yang's meta-analysis of 12 population-
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H. Li et al. / Journal of Epidemiology 27 (2017) 143e151 149based studies, which observed 1.16-times higher ERþ tumor risk
for women who experienced menarche younger than 12 years
old.39 Although our subgroup analysis on menopausal status did
not yield significant relationships, we noticed that the proportion
of early menarche was higher in luminal cases than in HER2-
enriched or triple-negative patients for both pre- and post-
menopausal women. Both our case-control study and meta-
analysis found significant heterogeneity of the associations be-
tween menarche age and breast tumor subtypes. This indicated
that menarche age may mainly contribute to the risk of luminal
tumor. The negative results of the stratified analysis may be
explained by the limited sample size in each layer. Both this case-
control study and meta-analysis in East Asians found that women
who had older menopausal age had higher risks of luminal and
ERPR tumors. This was consistent with the results of the
Nurses' Health Study of 121,700 participants from United Study
(for the three subtypes, HRs ranged from 1.01 to 1.07, with 95% CIs
excluding1).43 The mechanism for the role of menopausal age in
development of HER2-enriched and triple-negative tumors was
unclear. Our results need to be verified in a larger sample size in
East Asia.
Pregnancy initiates cellular differentiation in mammary glands
and lowers susceptibility to carcinogenesis.44 Previous studies
have observed a negative relationship between parity and breast
cancer.18,31,45e47 In our case-control study, the number of nullip-
arous women was small, especially in the sets of molecular sub-
types. Thus, it was unlikely that we would observe an effect of
nulliparity on tumor subtype. In the meta-analysis, which
included our data, we found that nulliparity increased risk only of
the luminal subtype. This finding is supported by Yang's pooled
analysis,39 Ma's meta-analysis of seven epidemiological studies,48
and Anderson's recent systematic review, which qualitatively
summarized the results of associations between reproductive
factors and molecular subtypes.11 Combined with the known ef-
fects of pregnancy, these results indicate that nulliparity may in-
crease the risk of breast cancer via a hormonal pathway.
In this case-control study, late age at first live birth increased
the risk of all three subtypes. However, in the meta-analysis, we
did not find an association between age at first live birth and any
breast cancer subtype. When we excluded one study from the
analysis, late age at first live birth showed a positive association
with risk of luminal tumor (OR1.33; 95%CI, 1.22e1.44). The asso-
ciations between age at first live birth and other subtypes in the
meta-analysis were stable, and the heterogeneity of the included
studies disappeared (P > 0.05). Then, we re-calculated the het-
erogeneity of associations between age at first delivery and tumor
subtypes and found that it was significant (P < 0.001) (data not
shown). In our case-control study, we observed that increased age
at first live birth was associated with risk of both pre- and post-
menopausal luminal tumor. This was accordant with Ma's meta-
analysis of nine population-based studies.48
Breastfeeding may increase the protective effect of pregnancy
by inducing terminal differentiation, removal of initiated breast
epithelial cells, excretion of carcinogenic agents, and delay in
ovulation.49 In the present case-control study, we found no as-
sociation between breastfeeding and any breast cancer molecular
subtype in total, pre-, or postmenopausal women. However, the
meta-analysis demonstrated that lack of breastfeeding increased
the risk of all breast cancer subtypes, and the effect of non-
breastfeeding on ERPR tumor risk was significantly stronger
than that on risk of the luminal subtype. This accords with Ma's
meta-analysis48 and Anderson's recent systematic review.11 Our
results indicate that age at first delivery and breastfeeding may
affect breast cancer risk via various mechanisms.
H. Li et al. / Journal of Epidemiology 27 (2017) 143e151150With increasing economic prosperity, more East Asian women
exercise reproductive control. In China, for example, between 1982
and 2001, the proportion of women whose first live birth occurred
at 30 years of age or older increased from 1.35% to 4.86%,50 and the
prevalence of non-lactation in premenopausal women increased
from 9.5% to 22.7% from births in 1950 to 1970.13 This information,
combined with our results, suggests the role of health education in
childbearing choices and the need to encourage breastfeeding for
young Chinese mothers.
This case-control study has several limitations. First, some of the
subsets of interest were limited in sample size, and other
population-based studies are needed to replicate the results. Sec-
ond, only 20% of “þ2” patients were FISH-tested, so a non-
differential bias may exist. Considering that fewer than 20% of
womenwith “þ2” were diagnosed as HER2-positive using FISH, the
non-differential bias may be small. Third, in this study, we included
common risk factors that were previously hypothesized to affect
peripheral estrogen levels. Although we adjusted for the most
important known risk factors (age and family history of breast
cancer) for breast cancer, several other well-known risk factors for
breast cancer were not included. Further study including other
well-known risk factors is needed to verify our results. In addition,
we measured BMI when patients were admitted to the hospital for
the first time. Since their body weight might be changed by pres-
ence of breast cancer, the observed associations might be due to
reverse causality, and our study design did not allow us to make
definitive causal inferences.
Sichuan Cancer Hospital is the leading tertiary hospital
providing diagnosis, treatment, and routine follow-up care for pa-
tients with breast cancer in Sichuan Province, and Chengdu Chil-
dren's and Women's Hospital is the leading tertiary institution
providing health care for women and children in Sichuan Province.
In Sichuan Cancer Hospital, more than 70% of patients came from
Chengdu and areas within a radius of <150 km, and the controls
were community women who attended routine physical exami-
nations in Chengdu or suburban areas nearby. Thus, we believe that
most women in the control group would go to Sichuan Cancer
Hospital if they had breast cancer, so the controls represent the
source population of cases to a certain degree. Our results in this
case-controls study may be specific to Chengdu. In order to better
observe the association between BMI, reproductive factors, and
breast cancer subtypes, we conducted a meta-analysis in East Asia
women. The results of studies included in the meta-analysis were
homogenous, and the effects for most of the risk factors were sta-
ble. Thus, we believe the results of meta-analysis were acceptable.
In summary, for East Asian women, overweight, late meno-
pause, and lack of breastfeeding appear to increase risks of both
luminal and ERPR tumors. Early menarche and nulliparity may
contribute chiefly to the risk of luminal tumor. In our study, these
associations were not impacted by menopausal status. Most of
these findings were similar to those in studies conducted in
Western countries. In addition, late age at first live birth may in-
crease the risk of luminal tumor, which needs to be evaluated
further in a larger East Asian population.Conflicts of interest
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